Antibacterial Agents TRIZ Cases

Oxadiazole derivatives target S1P1 receptors to resolve selectivity trade-offs in autoimmune disease therapies.

Mohs-hardness matched glidants coat clavulanic acid agglomerates to eliminate interparticle friction, ensuring weight uniformity during tablet compression.

A bioadhesive vaginal tablet uses a composite hydrophilic matrix to accelerate hydration and promote rapid solid-gel transition for controlled drug release.

Nucleic acid recognition moieties bind target sequences to assemble active effector structures within cells.

Macrocyclic compounds stimulate gastrointestinal motility without triggering growth hormone secretion, resolving side effects in metabolic disorders.

Hexyl 5-ALA ester composition minimizes pain and erythema during photodynamic therapy by adjusting concentration and light fluence.

Arp2/3 inhibitors block NTHI uptake by epithelial cells, addressing antibiotic resistance in otitis media.

TNFR1 antagonists resist proteolytic degradation via amino acid substitutions, extending half-life in inflammatory disease treatment.

Fluorinated copolymers dissolve in low toxicity solvents to create stable emulsions without toxic surfactants.

Boronic acid compounds bind the UCH catalytic domain to treat pathogenic infections and neurodegenerative disorders.

Pyrimido[5,4-d]pyrimidine derivatives target tyrosine kinases to resolve the lack of effective enzyme inhibitors for treating abnormal cell growth.

LPA2 receptor agonists bind epithelial receptors to form complexes with NHERF2, blocking CFTR channels and stopping fluid loss in secretory diarrhea.

One-pot synthesis of 2-(benzo[d]oxazol-2-yl)-N′-(picolinoyloxy)acetimidamide uses carbonyldiimidazole to boost yield and cut reaction time.

Hydroxyethyl side chains shield the beta-lactam ring from enzymatic deactivation, restoring efficacy against resistant gram-negative bacteria.

Dimeric secretory IgA and pentameric secretory IgM neutralize Clostridium difficile toxins while preserving intestinal flora integrity.

Detect host immune protein biomarkers in sputum via lateral flow assays, resolving the trade-off between diagnostic accuracy and test duration.

Microbially enhanced protein feed reduces Vibrio infections and boosts shrimp survival rates.

Luminescent particles convert penetrating initiation energy into localized light, enabling uniform curing of shaded areas and reducing overall cure time.

Multipotent adult progenitor cells differentiate into multiple cell types to treat brain injuries without requiring adjunctive immunosuppressive treatment.

A recombinant Listeria strain delivers tumor and angiogenic antigens to trigger a robust immune response.

Targeted mutation of the ClbP peptidase domain eliminates colibactin genotoxicity while preserving antibacterial activity against pathogens.

Formula I imidazopyridines block SSAO enzyme action to reduce pro-inflammatory products and immune cell extravasation in inflammatory diseases.

Screening method identifies companion compounds by modulating Rv0324 and Rv0880 transcription factors to overcome bacterial tolerance.

Replacing chemical sanitizers, these bacteriophages eliminate E. coli contamination without harming beneficial microbes or generating environmental residues.

Synthesizing a new pyridine derivative via one-pot reaction overcomes drug resistance in Staphylococcus aureus and Escherichia coli.

Salmonella milRNAs regulate host immune genes, enabling accurate diagnosis of intracellular infections without prolonged bacterial culture.

Removing lysogenic genes forces lytic replication while CRISPR arrays target essential genes, overcoming temperate phage evasion of antibiotic resistance.

A phyto-mixture of Bidens, Stachytarpheta, and Bursera extracts inhibits immune reactions.

Controlled seed crystallization with antisolvents yields stable, non-hygroscopic eravacycline bis-hydrochloride powder.

Wet oxidation of carbohydrates yields a purified fulvic acid composition that removes harmful metals to ensure pharmaceutical safety.

Combining phytantriol and erythrulose creates a synergistic antimicrobial system for topical formulations.

Complexing antibiotics with saccharides and transition metals overcomes Mycobacterium tuberculosis resistance while lowering dosages.

Fusion proteins covering the chlamydial genome identify immunodominant antigens for diagnostic and therapeutic applications.

Pulsed tiacumicin dosing regimens eliminate Clostridium difficile while allowing gut Bifidobacteria recovery to reduce recurrence rates.

Pulse combustion atomization spray drying processes maintain bacteriophage viability during liquid-to-solid conversion.

IL-27 signaling drives co-inhibitory receptor expression in T cells through Prdm1 and c-Maf transcription factors.

Modified monoclonal antibodies bind human IP-10 with high affinity to inhibit receptor interaction and calcium flux.

Formula I organosulfur compounds enhance antimicrobial activity and wound healing through specific phenyl and cycloalkyl substitutions.

Recombinant Ov-ASP proteins replace conventional adjuvants to overcome insufficient cytotoxic responses against intracellular pathogens.

Reduced phenothiazine overcomes electrostatic repulsion in Gram-negative bacteria, enabling membrane penetration and effective pathogen inhibition.

A plasticized chewable formulation uses extrusion to create a stable matrix without free water.

Merging bispecific antibodies with checkpoint inhibitors overcomes short half-life limitations while enhancing therapeutic efficacy against cancer.

Combining inactivated Edwardsiella tarda strains with Streptococcus cells enhances phagocytic activity to prevent edwardsiellosis and streptococcosis.

Synthesized phenytoin derivative combats drug-resistant bacteria and fungi through structural modification of the core scaffold.

Epigenetic imprinting modifies bacteriophage infectivity ranges, enabling selective killing of pathogenic bacteria while sparing beneficial strains.

Orthogonal protection enables lysine and arginine monomer assembly, overcoming peptide instability and resistance.

Modified polymyxin compounds with altered N-terminal groups reduce nephrotoxicity while maintaining potent activity against resistant Gram-negative bacteria.

Ionizing irradiation stimulates bacterial membrane vesicle production, eliminating toxic residues from chemical methods while maintaining high yield and purity.

Novel hydroxamate derivatives inhibit histone deacetylase activity through specific structural modifications.